{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:55:27Z","timestamp":1761238527011,"version":"3.38.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p> Neisseria meningitidis is a major cause of meningitis and septicemia globally. Vaccines directed against N. meningitidis serogroup B (MenB) have been used to control sporadic and sustained disease in industrialized and non-industrialized countries. Early outer membrane vesicle (OMV) vaccines effectively reduced MenB disease in countries such as Norway, New Zealand, and France; however, these vaccines were highly specific for their targeted outbreak strain, did not elicit a durable immune response, and were ineffective for widespread use due to the diversity of MenB-disease-causing isolates. Recently developed recombinant protein-based MenB vaccines that target conserved surface proteins have the potential to induce a broader immune response against the diversity of disease-causing strains. Given the deleterious consequences and sporadic nature of MenB disease, the use of optimal vaccination strategies is crucial for prevention. Reactive vaccination strategies used in the past have significant limitations, including delayed implementation, substantial use of resources, and time constraints. The broad coverage potential of recombinant protein-based MenB vaccines suggests that routine use could result in a reduced burden of disease. Despite this, routine use of MenB vaccines is currently limited in practice. <\/jats:p>","DOI":"10.1177\/2515135518781757","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T07:04:44Z","timestamp":1529564684000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control"],"prefix":"10.1177","volume":"6","author":[{"given":"Paul","family":"Balmer","sequence":"first","affiliation":[{"name":"Senior Medical Director, Pfizer Vaccines Medical Development and Scientific\/Clinical Affairs, Pfizer Inc., 500 Arcola Road, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[{"name":"Vice President, Global Meningococcal Vaccines, Pfizer Vaccines Medical Development and Scientific\/Clinical Affairs, Pfizer Inc., 500 Arcola Road, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"bibr1-2515135518781757","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network, Neisseria meningitidis, http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening14.pdf (2014, accessed 19 July 2017)."},{"key":"bibr2-2515135518781757","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Surveillance%20of%20IBD%20in%20Europe%202012.pdf (2012, accessed 4 October 2017)."},{"key":"bibr3-2515135518781757","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease, http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/mening.pdf (2015, accessed 23 March 2017)."},{"key":"bibr4-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)67932-4"},{"key":"bibr5-2515135518781757","doi-asserted-by":"crossref","first-page":"30175","DOI":"10.2807\/1560-7917.ES.2016.21.12.30175","volume":"21","author":"Campbell H","year":"2016","journal-title":"Euro Surveill"},{"key":"bibr6-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"bibr7-2515135518781757","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24129"},{"key":"bibr8-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70027-5"},{"key":"bibr9-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix154"},{"key":"bibr10-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1790"},{"key":"bibr11-2515135518781757","first-page":"606","volume":"64","author":"Soeters HM","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr12-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00217-0"},{"key":"bibr13-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pir003"},{"key":"bibr14-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70251-6"},{"key":"bibr15-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1130628"},{"key":"bibr16-2515135518781757","doi-asserted-by":"publisher","DOI":"10.3201\/eid1206.051297"},{"key":"bibr17-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17"},{"key":"bibr18-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"bibr19-2515135518781757","unstructured":"Novartis. Bexsero\u00ae (package insert). Cambridge, MA: Novartis, 2016."},{"key":"bibr20-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.033"},{"key":"bibr21-2515135518781757","unstructured":"Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Trumenba\u00ae (package insert). Philadelphia, PA: Wyeth Pharmaceuticals Inc. 2016."},{"key":"bibr22-2515135518781757","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34293"},{"key":"bibr23-2515135518781757","unstructured":"US Food and Drug Administration. Summary basis for regulatory action, https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM548305.pdf (2017, accessed 19 March 2017)."},{"key":"bibr24-2515135518781757","unstructured":"Pfizer Canada. Trumenba\u00ae, Product monograph (package insert). Kirkland, Quebec, CN: Pfizer Canada, 2017."},{"key":"bibr25-2515135518781757","unstructured":"European Medicines Agency. EPAR summary for the public: Trumenba. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004051\/WC500228998.pdf (2017, accessed June 4, 2018)."},{"key":"bibr26-2515135518781757","unstructured":"BusinessWire. European Commission Approves Pfizer\u2019s TRUMENBA\u00ae to Help Prevent Meningococcal Group B Disease in Adolescents and Adults, https:\/\/www.businesswire.com\/news\/home\/20170530005731\/en\/European-Commission-Approves-Pfizer%E2%80%99s-TRUMENBA%C2%AE-Prevent-Meningococcal (2017, accessed June 4, 2018)."},{"key":"bibr27-2515135518781757","unstructured":"Australian Government Department of Health TGA. Prescription medicines: Registration of new chemical entities in Australia, https:\/\/www.tga.gov.au\/prescription-medicines-registration-new-chemical-entities-australia (2017, accessed 23 October 2017)."},{"key":"bibr28-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"bibr29-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"bibr30-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.034"},{"key":"bibr31-2515135518781757","first-page":"67","volume":"14","author":"Fredriksen JH","year":"1991","journal-title":"NIPH Ann"},{"key":"bibr32-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"bibr33-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00047-06"},{"key":"bibr34-2515135518781757","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Bexsero suspension for injection in prefilled syringe, https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015\u201309\/bexsero_en_ct13508_val.pdf (2014, accessed 20 July 2017)."},{"key":"bibr35-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1086\/603552"},{"key":"bibr36-2515135518781757","unstructured":"New Zealand Ministry of Health. Meningococcal B immunisation programme and MeNZB\u2122 vaccine, http:\/\/www.health.govt.nz\/our-work\/preventative-health-wellness\/immunisation\/immunisation-programme-decisions\/meningococcal-b-immunisation-programme-and-menzbtm-vaccine (2008, accessed 27 March 2017)."},{"key":"bibr37-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00591-1"},{"key":"bibr38-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.023"},{"key":"bibr39-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm147"},{"key":"bibr40-2515135518781757","unstructured":"New Zealand Ministry of Health. The epidemiology of meningococcal disease in New Zealand, https:\/\/surv.esr.cri.nz\/PDF_surveillance\/MeningococcalDisease\/2013\/2013AnnualRpt.pdf (2013, accessed 2 November 2017)."},{"volume-title":"Impact of material and social deprivation on serogroup B invasive meningococcal disease (IMD-B) incidence and outcomes in the province","author":"Tapiero B","key":"bibr41-2515135518781757"},{"key":"bibr42-2515135518781757","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network: Streptococcus pneumoniae, http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu14.html (2014, accessed 11 November 2016)."},{"key":"bibr43-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.20.1906"},{"key":"bibr44-2515135518781757","unstructured":"Terry L. The Oregonian\/Oregon Live. OSU hit with 6th case of meningococcal disease; all students under 26 will need a vaccination. http:\/\/www.oregonlive.com\/health\/index.ssf\/2017\/12\/osu_hit_with_6th_case_of_menin.html (2017, accessed 12 February 2018)."},{"key":"bibr45-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-017-0587-4"},{"key":"bibr46-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1080\/07448481.2017.1285772"},{"key":"bibr47-2515135518781757","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.161870"},{"key":"bibr48-2515135518781757","unstructured":"Oregon Health Authority. 2015 meningococcal update, https:\/\/public.health.oregon.gov\/DiseasesConditions\/DiseasesAZ\/MeningococcalDisease\/Pages\/Meningococcal-Update.aspx (2015, accessed 31 August 2016)."},{"key":"bibr49-2515135518781757","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease, https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2015 (2017, accessed 13 February 2018)."},{"key":"bibr50-2515135518781757","unstructured":"Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK, https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf (2014, accessed 2 October 2017)."},{"key":"bibr51-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31921-3"},{"key":"bibr52-2515135518781757","unstructured":"Health Service Executive. Meningococcal B, https:\/\/www.hse.ie\/eng\/health\/immunisation\/pubinfo\/newschedule\/VPDs\/menb\/ (2016, accessed 23 October 2017)."},{"key":"bibr53-2515135518781757","unstructured":"European Centre for Disease Prevention and Control. Meningococcal disease: recommended vaccinations, https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1 (accessed 2 January 2017)."},{"key":"bibr54-2515135518781757","unstructured":"ANSA. Italy\u2019s new vaccination plan widens cover, http:\/\/www.ansa.it\/english\/news\/2017\/01\/20\/italys-new-vaccination-plan-widens-cover_7098a6f2-f744\u20134d25\u201396cf-a0e6b28a0d68.html (2017, accessed 23 March 2018)."},{"key":"bibr55-2515135518781757","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6441a3"},{"key":"bibr56-2515135518781757","first-page":"608","volume":"64","author":"Folaranmi T","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr57-2515135518781757","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6619a6"},{"key":"bibr58-2515135518781757","unstructured":"Government of Canada. Canadian immunization guide. Part 4. Active vaccines, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines.html (2016, accessed 2 May 2017)."},{"key":"bibr59-2515135518781757","unstructured":"Australian Government Department of Health. Australian Technical Advisory Group on Immunisation (ATAGI) Statement. Advice for immunisation providers regarding the use of Bexsero, http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/atagi-advice-bexsero. (2015, accessed 19 July 2017)."},{"key":"bibr60-2515135518781757","unstructured":"European Centre for Disease Prevention and Control. Recommended immunisations for meningococcal disease, http:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx (2017, accessed 20 July 2017)."},{"key":"bibr61-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60842-4"},{"key":"bibr62-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.034"},{"key":"bibr63-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5725"},{"key":"bibr64-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1160177"},{"key":"bibr65-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123383"},{"key":"bibr66-2515135518781757","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.004"},{"key":"bibr67-2515135518781757","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23888"},{"key":"bibr68-2515135518781757","unstructured":"Le Haut Conseil de la sant\u00e9 publique. [Vaccination against serogroup B invasive meningococcal disease the role of Bexsero vaccination], www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspr20131025_vaccmeningocoqueBBexsero.pdf (2013, accessed 10 April 2018)."},{"key":"bibr69-2515135518781757","unstructured":"Australian New Zealand Clinical Trials Registry, https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=371948 (2017, accessed 2 October 2017)."}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135518781757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2515135518781757","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135518781757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:10:56Z","timestamp":1740762656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2515135518781757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1177\/2515135518781757"],"URL":"https:\/\/doi.org\/10.1177\/2515135518781757","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"type":"print","value":"2515-1355"},{"type":"electronic","value":"2515-1363"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}